Post Profile

Roche say cancer drug Alecensa gets breakthrough therapy designation

ZURICH (Reuters) - Roche said on Tuesday its lung cancer drug Alecensa (alectinib), developed by its Genentech unit, received a second breakthrough therapy designation (BTD) from the U.S. Food and Drug Administration (FDA) for its anaplastic lymphoma kinase (ALK) inhibitor.
read more


Related Posts

University of Pennsylvania's Personalized Cellular Therapy for Leukemia Receives FDA's Breakthrough Therapy Designation

Health : Newswise Medical News

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymph...

Abbott Receives FDA Approval For ALK Gene Test For Lung Cancer Therapy Selection

Health : Medical News Today

Abbott (NYSE: ABT) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-s...

Fake Avastin: FDA and Roche Warn of Counterfeit Cancer Drugs

Health : Time: Healthland

The maker of the widely prescribed cancer drug Avastin is warning doctors and patients about counterfeit vials of the product that have been distributed in the U.S. Roche’s Genentech unit said Tuesday that the fake products do not c...

Fake Avastin (Bevacizumab) Found In USA

Health : Medical News Today

Fake cancer drug, Avastin (bevacizumab) has been distributed in the USA, according to statement issued by Roche, Genentech and the FDA (Food and Drug Administration) today. Roche warns that the counterfeit medication does not have t...

New Drug Applications Submitted In The United States And Europe For Vemurafenib In Advanced Skin Cancer

Health : Medical News Today

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) for people with ...


Copyright © 2016 Regator, LLC